Volume 3.18 | May 15

Pulmonary Cell News 3.18 May 15, 2014
Pulmonary Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Pulmonary Cell News on Twitter
Viral and Host Factors Determine Innate Immune Responses in Airway Epithelial Cells from Children with Wheeze and Atopy
Nasal epithelial cells, but not tracheal epithelial cells, from children with wheeze and/or atopy produced less interferon (IFN)-β, but not IFN-λ, in response to respiratory syncytial virus infection; this was associated with higher viral shedding. [Thorax] Full Article
Listen Now: Podcast on ALDH in Breast Cancer Treatment Response
PUBLICATIONS (Ranked by impact factor of the journal)
Alterations of Bronchial Epithelial Metabolome by Cigarette Smoke Are Reversible by an Antioxidant UPF1
Researchers aimed to determine the dynamics of metabolome changes in human bronchial epithelial cells treated with cigarette smoke condensate and to test whether normal metabolism can be restored by synthetic antioxidants. [Am J Respir Cell Mol Biol] Abstract

Pim1 Kinase Protects Airway Epithelial Cells from Cigarette Smoke Induced Damage and Airway Inflammation
Human bronchial epithelial BEAS-2B cells were treated with cigarette smoke extract in presence or absence of Pim1 inhibitor, and assessed for loss of mitochondrial membrane potential, induction of cell death and release of HSP70. [Am J Physiol Lung Cell Mol Physiol] Abstract

Gene Expression Profiles Reveal Distinct Immunological Responses of Cobalt and Cerium Dioxide Nanoparticles in Two In Vitro Lung Epithelial Cell Models
Scientists performed a time kinetic study of gene expression profiles induced by these nanoparticles in alveolar A549 and bronchial BEAS-2B epithelial cells, and investigated possible immune system modulation. [Toxicol Lett] Abstract

Comparative Effects between Electronic and Cigarette Smoke in Human Keratinocytes and Epithelial Lung Cells
Skin and lung cells, the main targets of cigarette smoke (CS), were exposed to electronic cigarettes vapor and CS using an in vitro system. The cytotoxic effect of the exposure was analyzed in both cell types by ultrastructural morphology, Trypan Blue exclusion test and LDH assay. [Toxicol In Vitro] Abstract


Exposure to 9,10-Phenanthrenequinone Accelerates Malignant Progression of Lung Cancer Cells through Up-Regulation of Aldo-Keto Reductase 1B10
Researchers showed that treatment with high concentrations of 9,10-phenanthrenequinone evokes apoptosis of lung cancer A549 cells through production of reactive oxygen species. [Toxicol Appl Pharmacol] Abstract

Huaier Suppresses Proliferation and Induces Apoptosis in Human Pulmonary Cancer Cells via Upregulation of miR-26b-5p
Transfection of A549 cells with miR-26b-5p mimic inhibited proliferation and induced apoptosis, while transfection of Huaier-treated A549 cells with a miR-26b-5p inhibitor reversed the effects of Huaier. [FEBS Lett] Full Article

Cantharidin Induces Apoptosis of H460 Human Lung Cancer Cells through Mitochondria-Dependent Pathways
Researchers investigated the effect of cantharidin on the cell death via the induction of apoptosis in H460 human lung cancer cells. [Int J Oncol] Abstract

SchA-p85-FAK Complex Dictates Isoform-Specific Activation of Akt2 and Subsequent PCBP1-Mediated Post-Transcriptional Regulation of TGFβ-Mediated Epithelial to Mesenchymal Transition in Human Lung Cancer Cell Line A549
TGF-β induced epithelial to mesenchymal transition (EMT) in A549 cells concomitant with translational upregulation of disabled-2 and interleukin-like EMT inducer proteins through isoform-specific activation of Akt2 followed by phosphorylation of poly r(C) binding protein (PCBP1) at serine-43. [Tumor Biol] Abstract

mTeSR™1: Most Published Feeder-Free hPSC Maintenance Medium. Click to View Top Applications
The Evolving Dynamics of the Microbial Community in the Cystic Fibrosis Lung
The cystic fibrosis lung is a niche colonized by a diverse group of organisms, with a more limited number of species including P. aeruginosa dominating in adult patients. Whether all members of this microbial community play a direct or indirect role in pulmonary decline has yet to be fully elucidated, but investigations of their interactions with both co-colonizing species and with host cells are beginning to shed light on their virulence potential. [Environ Microbiol] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
New Study Shows High Sensitivity and Specificity for VisionGate’s LuCED® Test to Help Detect Lung Cancer Earlier
VisionGate Inc. announced that positive results from a clinical study of its LuCED lung test. The study demonstrates three major advantages to incorporating the LuCED lung test into the diagnostic algorithm: high sensitivity, exceedingly high specificity and the ability to detect cancer cells in stages I and II. [Press release from VisionGate Inc. discussing research to be presented at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting, Chicago] Press Release

Lilly’s Necitumumab Improves Overall Survival in Largest Ever Phase III Study in First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer
Lung cancer patients with metastatic squamous cell carcinoma have seen few treatment advancements over the last two decades, leaving these patients with a poor prognosis. Results from the largest ever Phase III trial in first-line squamous non-small cell lung cancer announced by Eli Lilly and Company provide the first detailed look at a potential new treatment option for these patients. [Press release from Eli Lilly and Company discussing research to be presented at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting, Chicago] Press Release

New Data for Boehringer Ingelheim’s Gilotrif® (Afatinib) Shows a Significant Improvement in Overall Survival in Lung Cancer Patients Whose Tumors Have the Most Common EGFR Mutation
Boehringer Ingelheim announced new overall survival data of two Phase III clinical trials (LUX-Lung 3 and LUX-Lung 6). Patients with advanced non-small cell lung cancer whose tumors have the most common epidermal growth factor receptor (EGFR) mutation lived longer if treated with first-line afatinib compared to chemotherapy. [Press release from Boehringer Ingelheim GmbH discussing research to be presented at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting, Chicago] Press Release

Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Showed Antitumor Activity in Previously Treated and Chemotherapy-Naïve Patients in Phase Ib Non-Small Cell Lung Cancer Trials
Bristol-Myers Squibb Company announced results from a Phase Ib study evaluating the safety and efficacy of its investigational PD-1 immune checkpoint inhibitor nivolumab as a single agent in patients with advanced non-small cell lung cancer who were previously treated and a Phase Ib study evaluating nivolumab as a single agent in chemotherapy-naïve patients. [Press release from Bristol-Myers Squibb Company discussing research to be presented at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting, Chicago] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the Human Immunology Portal.
AstraZeneca Initiates Phase III Immunotherapy Study for MEDI4736 in Patients with Lung Cancer
AstraZeneca announced the start of the Phase III program for MEDI4736, an immunotherapy in development for the treatment of non-small cell lung cancer and other cancers. [AstraZeneca] Press Release

$4 Million from Eli and Edythe Broad Foundation will Support UCLA Research
Two new gifts from The Eli and Edythe Broad Foundation to UCLA totaling $4 million will fund research in stem cell science and digestive diseases and support the recruitment of key faculty at two renowned research centers. [UCLA] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Targeting VEGF-Mediated Tumor Angiogenesis in Cancer Therapy
June 19-20, 2014
New York, United States

Visit our events page to see a complete list of events in the pulmonary cell community.
NEW Postdoctoral Research Fellow – Allergic Lung Inflammation (Singapore Immunology Network)

NEW Research Assistant Professor or Instructor – Pulmonary Disease (University of Illinois)

NEW Postdoctoral Fellowship – Malignant Progression of Lung Cancer (MD Anderson Cancer Center)

Research Fellow – Pulmonary Cancer (Mayo Clinic – Rochester)

Postdoctoral Researcher – Metabolomics of Pulmonary Medicine (Karolinska Institute)

Molecular Immunologist – COPD (GlaxoSmithKline)

Postdoctoral Positions – Pulmonary and Exercise Immunology (São Paulo Research Foundation)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Research Technologist – hPSC (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Pulmonary Cell News: Archives | Events | Contact Us